Philips BioTel Heart:
The Cardiac Data company

Rise above the data deluge with actionable insight for tailored patient care.

Clinical Care Programs


TAVR

Post-TAVR Cardiac Monitoring

TAVR - Transcatheter Aortic Valve Replacement

Solution:

Monitoring Cardiac Risk Following TAVR*​

10%

Post-TAVR Outpatients1
Mobile Cardiac Telemetry † Detected High-Grade Heart Block1

9%

of TAVR Outpatients Required Readmission for PPM Placement1†

6 Days1

(Range 3-24 Days)
Median Time Develop High-grade AV Block (DH-AVB) Post-Procedure
† Mobile Cardiac Telemetry utilized in this study was the ACT (Ambulatory Cardiac Telemetry) Monitor by BioTel Heart.
Reference: 1. Ream K, Sandhu A, Valle J, et al. Ambulatory Rhythm Monitoring to Detect Late High-Grade Atrioventricular Block Following Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2019;73(20):2538–2547. (Adapted from Illustration 44 A, p 2541)

Post-Discharge Risk of Heart Block

Recent studies have revealed the increasing awareness and concern with Heart Block after a patient undergoes a TAVR procedure, contributing to a higher 30-day mortality.1 The research shows delayed high-grade AV bock occurred in 10% of patients discharged after TAVR, and some as late as 24 days. This patient population has been identified as an ideal candidate to monitor to reduce the risks and implications of Heart Block.

Ambulatory Rhythm Monitoring to Detect Late High-Grade Atrioventricular Block Following Transcatheter Aortic Valve Replacement

Study
Assess the utility of MCT monitoring in identifying post-TAVR Delayed High-Grade Atrioventricular Block (DH-AVB) and associated risk factors

Method
Patients who did not have a pre-existing or an immediate post-TAVR permanent pacing device were discharged with a 30-day near-real time MCT monitor from BioTel Heart

Reference: 1. Ream K, Sandhu A, Valle J, et al. Ambulatory Rhythm Monitoring to Detect Late High-Grade Atrioventricular Block Following Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2019;73(20):2538–2547. (Adapted from Illustration 4 A, p 2541)​

Benefits:

Resources:



Stroke

Post-Cryptogenic Stroke Monitoring​

The BioTel Heart Stroke Patient Care Program offers Neurologists and Stroke Specialists with a simple solution to monitor cryptogenic stroke and TIA patients for the detection of silent Atrial Fibrillation.

Problem:

Lorem ipsum dolor

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do tempor incididunt ut labore et dolore magna aliqua. Nullam ac tortor vitae purus faucibus. Eu scelerisque felis imperdiet proin fermentum vel. Orci phasellus egestas tellus rutrum tellus pellentesque. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do tempor incididunt

Solution:

Benefits:

Program Features:

• Physician Notification with customization for first documentation of AF
• Simple online enrollment
• HIPAA secured WEB access for report viewing
• Educational tools to improve patient compliance
• Patch Technology for patient compliance and ease of use

Resources:



Telehealth

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do tempor incididunt ut labore et dolore magna aliqua. Nullam ac tortor vitae purus faucibus. Eu scelerisque felis imperdiet proin fermentum vel. Orci phasellus egestas tellus rutrum tellus pellentesque. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do tempor incididunt

Lorem ipsum dolor

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do tempor incididunt ut labore et dolore magna aliqua. Nullam ac tortor vitae purus faucibus. Eu scelerisque felis imperdiet proin fermentum vel. Orci phasellus egestas tellus rutrum tellus pellentesque. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do tempor incididunt

Problem:

Solution:

Benefits:

Resources:



AF Ablation​

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do tempor incididunt ut labore et dolore magna aliqua. Nullam ac tortor vitae purus faucibus. Eu scelerisque felis imperdiet proin fermentum vel. Orci phasellus egestas tellus rutrum tellus pellentesque. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do tempor incididunt

Lorem ipsum dolor

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do tempor incididunt ut labore et dolore magna aliqua. Nullam ac tortor vitae purus faucibus. Eu scelerisque felis imperdiet proin fermentum vel. Orci phasellus egestas tellus rutrum tellus pellentesque. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do tempor incididunt

Lorem ipsum dolor

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do tempor incididunt ut labore et dolore magna aliqua. Nullam ac tortor vitae purus faucibus. Eu scelerisque felis imperdiet proin fermentum vel. Orci phasellus egestas tellus rutrum tellus pellentesque. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do tempor incididunt

Problem:

Solution:

Benefits:

Resources:

Lorem ipsum dolor

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do tempor incididunt ut labore et dolore magna aliqua. Nullam ac tortor vitae purus faucibus. Eu scelerisque felis imperdiet proin fermentum vel. Orci phasellus egestas tellus rutrum tellus pellentesque. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do tempor incididunt

Lorem ipsum dolor

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do tempor incididunt ut labore et dolore magna aliqua. Nullam ac tortor vitae purus faucibus. Eu scelerisque felis imperdiet proin fermentum vel. Orci phasellus egestas tellus rutrum tellus pellentesque. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do tempor incididunt

Better Cardiac Data

1.2 M
Patients
Monitored
per Year
33 K
Physicians
Order per Month
2 K
Research
Completed Clinical Trials
40 K
Biosensors Shipped per Month ​
4 B
Data Transmission Heartbeats per Day ​
4
Logistics US Distribution Centers ​
5
Clinical Analysis US Monitoring Centers ​
400
Clinical Expertise Certified Technicians ​
7 M
Actionable Data Completed Clinical Trials ​

Patient care
programs

Delivering continuous care with improved outcomes

Ivermectin